Figure 6.

Da0324 or LINC01021-specific ASO treatment suppresses tumor growth of GC cells in vivo. A. Effects of Da0324 treatment on tumor volume in subcutaneous xenograft mouse models using KATO III cells. Tumor volume as measured by caliper of Da0324 (20 mg/kg, intraperitoneal injection every day) or vehicle administered for 18 days in a subcutaneous xenograft model. The data were expressed as mean ± SD. *, P < 0.05. B. Tumors were excised after 18 days of treatment. Images and weight of the dissected xenograft tumors are shown. C. Body weight of nude mice. D. Determination of tumor LINC01021 expression by qRT-PCR for both the control and treatment groups. The data were expressed as mean ± SD. **, P < 0.01. E. Western blot analysis of the protein expression of P53 and Bcl-2 in control or Da0324-treated mouse xenograft tumors. GAPGH was used as an internal control. F. Tumor volume of subcutaneous xenograft mouse models using KATO III cells treated with LINC01021-specific ASO or ASO-control. Tumor volume as measured by caliper of LINC01021-specific ASO or ASO-control (250 nmol/kg, intratumoral injection at three-day intervals) administered for 24 days in a subcutaneous xenograft model. The data were expressed as mean ± SD. *, P < 0.05. G. Tumors were excised after 24 days of treatment. Images and weight of the dissected xenograft tumors are shown. The data were expressed as mean ± SD. **, P < 0.01. H. Body weight of nude mice from ASO-control and ASO-LINC01021 treatment groups. I. Determination of LINC01021 expression by qRT-PCR in ASO-control and ASO-LINC01021 treatment xenografts. *, P < 0.05. J. Western blot analysis of the protein expression of P53 and Bcl-2 in tumor tissues from ASO-control and ASO-LINC01021 treatment groups. GAPGH was used as an internal control. ASO-ctrl, ASO-control; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.